Experimental cancer drug ZW171 tested in 32 patients, but study stopped early
Disease control
Terminated
This early-phase study tested a new drug called ZW171 in 32 people with advanced ovarian, lung, or other cancers that have a protein called mesothelin. The main goals were to check the drug's safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Zymeworks BC Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC